Clinical Trial Update: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation [Phase 4]

View source ↗

Summary

A Phase 4 multicenter study compares continuing current multiple sclerosis therapy versus transitioning to ofatumumab after elevated neurofilament levels in rel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab) (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 4 | Status: ACTIVE_NOT_RECRUITING